What is the most common predictor of nonadherence to treatment in schizophrenia?

• A. Anosognosia
• B. Severe side effects
• C. Lack of access to care
• D. Substance use disorder

Answer: (A)

The main idea is that lack of insight into illness is the strongest predictor of whether someone with schizophrenia will stick with their treatment. When a patient does not recognize that they are ill or understand the need for ongoing medication, they are much more likely to skip doses or stop treatment because they don’t see the benefit or feel they don’t need it. This lack of insight, or anosognosia, undermines motivation to adhere more consistently than other factors.

Severe side effects can drive nonadherence, but they don’t predict it as reliably because some patients may tolerate side effects if they believe the medication helps or if the illness itself is better controlled. Lack of access to care creates practical barriers to obtaining meds, yet adherence issues persist even when access is good, especially if insight is poor. Substance use disorder often coexists with nonadherence, but its predictive strength is typically not as strong as the impact of anosognosia.

In practice, addressing lack of insight—through psychoeducation, structured support, and, in some cases, strategies like long-acting injectable antipsychotics—can meaningfully improve adherence outcomes.